Join
Live feed
·
PRReleasevia Quantisnow
Tourmaline Bio Inc. logo

Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease

ByQuantisnow·Wall Street's wire, on your screen.
TRML· Tourmaline Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TRML (Tourmaline Bio Inc.) and more on Quantisnow.